Celon Pharma

Small molecules & peptides · Resistant depression; obesity

Overview

Integrated pharma whose Salmex inhaler cash-flow funds innovation. Intranasal esketamine (Falkieri) approaching registration in treatment-resistant depression; building a GLP-1 obesity peptide pipeline.

What they do

Celon Pharma is a vertically integrated, Warsaw Stock Exchange-listed pharmaceutical company that both manufactures established products and develops innovative drugs. Cash flow from its marketed Salmex inhaled respiratory product helps fund an R&D pipeline of small molecules and peptides across psychiatry, metabolism and other areas.

Lead program & status

Its flagship innovative candidate is Falkieri, a proprietary inhaled (dry-powder) esketamine for treatment-resistant depression. In a Phase II study in treatment-resistant bipolar depression, Falkieri met its primary endpoint with statistically significant MADRS reductions versus placebo and a favorable safety profile, with no manic switch reported. In 2024 Celon partnered with Tang Capital Management to form Novohale Therapeutics, intended to advance Falkieri into Phase III for bipolar depression. Alongside its CNS work, Celon is building a metabolic pipeline including GLP-1-based obesity peptide candidates, reflecting a strategic move into one of the largest current therapeutic markets.

Why it matters

Celon is one of the few Polish companies pairing real commercial revenue with genuine innovation. A registered inhaled esketamine and a credible GLP-1 obesity program would diversify it well beyond its generics and respiratory base. Investors should note Phase III remains ahead.

FAQ

What is Falkieri?

Falkieri is Celon Pharma's proprietary inhaled (dry-powder) esketamine candidate developed for treatment-resistant depression, including treatment-resistant bipolar depression, where it met its Phase II primary endpoint.

How does Celon Pharma fund its innovation pipeline?

Celon is an integrated pharma whose marketed products, notably the Salmex respiratory inhaler, generate cash flow that helps fund its innovative drug development.

Is Celon working on obesity treatments?

Yes. Celon is developing a metabolic pipeline that includes GLP-1-based peptide candidates aimed at obesity, in addition to its CNS programs.

Company website / source ↗ Open the interactive map →